Register
SGLT2 Inhibitors for Diabetes Safe, Effective in Older Adults |
Journal Updates
eMediNexus Coverage from: 
SGLT2 Inhibitors for Diabetes Safe, Effective in Older Adults

0 Read Comments                

Sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes appear to be as safe and effective in people aged 65 years and older as in younger individuals, new research suggests.

Findings from a real-world observational study of 50 older adults with type 2 diabetes were recently presented at the International Diabetes Federation (IDF) Congress 2019. With SGLT2 inhibitor treatment, average A1c level dropped from 8.5% to 7.3% (P < .01), body weight was reduced from 91.0 kg to 84.7 kg (P < .01), systolic blood pressure from 134.5 mmHg to 130.4 mmHg (P = .02), and diastolic blood pressure from 76.2 mmHg to 73.3 mmHg (P = .04).

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now